- 全部删除
- 您的购物车当前为空
Aganepag, a potent Prostanoid EP2 receptor agonist, exhibits remarkable selectivity with an EC50 of 0.19 nM, demonstrating no activity at the EP4 receptor. Its applications are primarily in the fields of wound healing, scar reduction, scar prevention, and the treatment and prevention of wrinkles.
Aganepag, a potent Prostanoid EP2 receptor agonist, exhibits remarkable selectivity with an EC50 of 0.19 nM, demonstrating no activity at the EP4 receptor. Its applications are primarily in the fields of wound healing, scar reduction, scar prevention, and the treatment and prevention of wrinkles.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 13,300 | 3-6月 |
Aganepag 相关产品
产品描述 | Aganepag, a potent Prostanoid EP2 receptor agonist, exhibits remarkable selectivity with an EC50 of 0.19 nM, demonstrating no activity at the EP4 receptor. Its applications are primarily in the fields of wound healing, scar reduction, scar prevention, and the treatment and prevention of wrinkles. |
靶点活性 | EP2:0.19 nM (EC50) |
体外活性 | Aganepag (Compound 3) is a potent Prostanoid EP2 receptor agonist, with an EC50 of 0.19 nM. It shows no activity at EP4. Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention[1]. |
别名 | AGN 210937 |
分子量 | 429.57 |
分子式 | C24H31NO4S |
CAS No. | 910562-18-4 |
密度 | 1.212 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容